Search

Your search keyword '"Merker, M."' showing total 7 results
Start Over Author "Merker, M." Journal bone marrow transplantation
7 results on '"Merker, M."'

2. Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease

Author

Thiel, U., primary, Schober, S. J., additional, Ranft, A., additional, Gassmann, H., additional, Jabar, S., additional, Gall, K., additional, von Lüttichau, I., additional, Wawer, A., additional, Koscielniak, E., additional, Diaz, M. A., additional, Ussowicz, M., additional, Kazantsev, I., additional, Afanasyev, B., additional, Merker, M., additional, Klingebiel, T., additional, Prete, A., additional, Gruhn, B., additional, Bader, P., additional, Jürgens, H., additional, Dirksen, U., additional, Handgretinger, R., additional, Burdach, S., additional, and Lang, P., additional

Published
2021
Full Text
View/download PDF

3. CLINICAL IMPACT OF POST-TRANSPLANT CHIMERISM MONITORING IN CD33/34 BONE MARROW SUBPOPULATIONS AND WHOLE PERIPHERAL BLOOD IN PEDIATRIC AML: PROSPECTIVE COMPARISON OF HIGHLY SENSITIVE REAL TIME SEQUENCE POLYMORPHISM PCR VERSUS GOLD-STANDARD STR-PCR: PH-O097

Author

Willasch, Manfred A., Rettinger, E., Zabel, M., Kreyenberg, H., Meyer, V., Merker, M., Borkhardt, A., Metzler, M., Kremens, B., Strahm, B., Woessmann, W., Mauz-Koerholz, C., Gruhn, B., Burdach, S., Albert, M., Schlegel, P.-G., Klingebiel, T., and Bader, P.

Published
2014

4. No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease

Author

Thiel, U., primary, Schober, S. J., additional, Ranft, A., additional, Gassmann, H., additional, Jabar, S., additional, Gall, K., additional, von Lüttichau, I., additional, Wawer, A., additional, Koscielniak, E., additional, Diaz, M. A., additional, Ussowicz, M., additional, Kazantsev, I., additional, Afanasyev, B., additional, Merker, M., additional, Klingebiel, T., additional, Prete, A., additional, Gruhn, B., additional, Bader, P., additional, Jürgens, H., additional, Dirksen, U., additional, Handgretinger, R., additional, Burdach, S., additional, and Lang, P., additional

Published
2021
Full Text
View/download PDF

5. Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience

Author

Willasch, A M, primary, Salzmann-Manrique, E, additional, Krenn, T, additional, Duerken, M, additional, Faber, J, additional, Opper, J, additional, Kreyenberg, H, additional, Bager, R, additional, Huenecke, S, additional, Cappel, C, additional, Bremm, M, additional, Pfirrmann, V, additional, Merker, M, additional, Ullrich, E, additional, Bakhtiar, S, additional, Rettinger, E, additional, Jarisch, A, additional, Soerensen, J, additional, Klingebiel, T E, additional, and Bader, P, additional

Published
2016
Full Text
View/download PDF

6. AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?

Author

Bakhtiar S, Salzmann-Manrique E, Hutter M, Krenn T, Duerken M, Faber J, Reinhard H, Kreyenberg H, Huenecke S, Cappel C, Bremm M, Pfirrmann V, Merker M, Barnbrock A, Schöning S, Willasch AM, Rettinger E, Soerensen J, Klingebiel TE, Jarisch A, and Bader P

Subjects
Adolescent, Adult, Allografts, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Infant, Male, Recurrence, Remission Induction, Retrospective Studies, Risk Factors, Survival Rate, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Abstract

Allogeneic hematopoietic stem cell transplantation (alloHSCT) has become a well-established treatment option for many patients suffering from malignant and non-malignant diseases. In the past decade, high-resolution HLA-typing, remission surveillance, pre-emptive immune intervention, and standardisation in supportive care measures have substantially improved transplant outcomes. This retrospective study evaluated transplant procedures in 162 paediatric patients with acute lymphoblastic leukaemia (n = 124) or acute myeloid leukaemia (n = 38) who received their first alloHSCT in our institution over an 11-year period. We observed a significant reduction in risk of non-relapse mortality (NRM) over time (HR = 0.34, 95% CI 0.12-0.98; P = 0.05), the 4-year NRM estimate decreased from 20% in 2005-2008 to 7% in 2012-2016 (P = 0.02) and an increase in survival after relapse. There was no significant difference in patients who received a graft from a sibling, haplo, or an unrelated donor with regard to their overall survival (P = 0.45), event-free survival (P = 0.61), and non-relapse mortality (P = 0.19). Our data suggest that a specific transplant infrastructure with a highly experienced team in an accredited transplant centre likely contributes to better transplant outcomes for acute leukaemia patients in complete remission regardless of donor type.

Published
2019
Full Text
View/download PDF

7. Haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk soft tissue sarcomas: results of a single-center prospective trial.

Author

Merker M, Meister MT, Rettinger E, Jarisch A, Soerensen J, Willasch A, Huenecke S, Cappel C, Bremm M, Salzmann-Manrique E, Krenn T, Rossig C, Kremens B, Koscielniak E, Klingebiel T, and Bader P

Subjects
Female, Humans, Male, Prognosis, Prospective Studies, Sarcoma pathology, Survival Rate, Hematopoietic Stem Cell Transplantation methods, Sarcoma therapy, Transplantation Conditioning methods, Transplantation, Homologous methods
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results